Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 4/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4842030 | 0.95 | PTPN1 (0.40) | MAPK1POLBSLC6A4SLC6A3PTPN1 | |
| SCHEMBL5251613 | 0.82 | MAPK1 (0.38) | MAPK1MAPTTP53ALDH1A1SMN1; SMN2 | |
| SCHEMBL4847727 | 0.81 | ALDH1A1 (0.41) | MAPK1SLC6A4SLC6A3ALOX5MAPT | |
| SCHEMBL4847452 | 0.81 | ALDH1A1 (0.41) | MAPK1SLC6A4SLC6A3ALOX5MAPT | |
| SCHEMBL5246783 | 0.77 | MAPK1 (0.38) | MAPK1MAPTTP53ALDH1A1SMN1; SMN2 | |
| SCHEMBL4845574 | 0.77 | MAPK1 (0.41) | MAPK1SLC6A4SLC6A3MAPTTP53 | |
| SCHEMBL4843861 | 0.74 | ALDH1A1 (0.43) | MAPTALDH1A1SMN1; SMN2MEN1GAA | |
| SCHEMBL4846600 | 0.72 | MAPK1 (0.41) | MAPK1SLC6A4SLC6A3MAPTTP53 | |
| SCHEMBL9949074 | 0.71 | CA12 (0.54) | MAPK1SLC6A4SLC6A3ALOX5CA12 | |
| SCHEMBL962986 | 0.71 | MAPT (0.50) | MAPK1SLC6A4SLC6A3ALOX5CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7435834-B2 | 2-thia-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof | GLAXOSMITHKLINE ISTRAZIVACKI CENTER ZAGREB D.O.O. (HR) | 2008-10-14 | — | — | US | claimed |
| EP-1684702-B1 | USE OF 2-THIA-DIBENZO[E,H]AZULENES FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | GLAXOSMITHKLINE ZAGREB (HR) | 2007-09-19 | — | — | EP | claimed |
| US-20060241099-A1 | USE OF 2-THIA-DIBENZO[E,H]AZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2006-10-26 | — | — | US | claimed |
| EP-1509530-B1 | 2-THIA-DIBENZOAZULENES AS INHIBITORS OF TUMOUR NECROSIS FACTOR PRODUCTION AND INTERMEDIATES FOR THE PREPARATION THEREOF | PLIVA ISTRAZIVACKI INST D O O (HR) | 2006-03-15 | — | — | EP | claimed |
| US-20050182126-A1 | 2-Thia-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof | PILVA-ISTRAZIVACKI INSTITUT D.O.O. | 2005-08-18 | — | — | US | claimed |
| US-20050131056-A1 | 2- thia-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the preparation thereof | PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2005-06-16 | — | — | US | claimed |
| US-7435834-B2 | 2-thia-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof | GLAXOSMITHKLINE ISTRAZIVACKI CENTER ZAGREB D.O.O. (HR) | 2008-10-14 | — | — | US | disclosed |
| EP-1684702-B1 | USE OF 2-THIA-DIBENZO[E,H]AZULENES FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | GLAXOSMITHKLINE ZAGREB (HR) | 2007-09-19 | — | — | EP | disclosed |
| US-20060241099-A1 | USE OF 2-THIA-DIBENZO[E,H]AZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2006-10-26 | — | — | US | disclosed |
| US-20050182126-A1 | 2-Thia-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof | PILVA-ISTRAZIVACKI INSTITUT D.O.O. | 2005-08-18 | — | — | US | disclosed |
| US-20050131056-A1 | 2- thia-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the preparation thereof | PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2005-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182126-A1 | 2-Thia-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof | IL1A, TNF, IL1B | MAPK1 349/4885POLB 3496/4885SLC6A4 4706/4885 |
| US-20060241099-A1 | USE OF 2-THIA-DIBENZO[E,H]AZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | DBH, MAOB, BCHE | MAPK1 3036/4885POLB 3561/4885SLC6A4 117/4885 |
| US-20050131056-A1 | 2- thia-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the preparation thereof | IL1A, TNF, IL1B | MAPK1 369/4885POLB 3505/4885SLC6A4 4707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.